Predicting beneficial effects of atomoxetine and citalopram on response inhibition in Parkinson's disease with clinical and neuroimaging measures

Recent studies indicate that selective noradrenergic (atomoxetine) and serotonergic (citalopram) reuptake inhibitors may improve response inhibition in selected patients with Parkinson's disease, restoring behavioral performance and brain activity. We reassessed the behavioral efficacy of these...

Descripción completa

Detalles Bibliográficos
Autores principales: Ye, Zheng, Rae, Charlotte L., Nombela, Cristina, Ham, Timothy, Rittman, Timothy, Jones, Peter Simon, Rodríguez, Patricia Vázquez, Coyle‐Gilchrist, Ian, Regenthal, Ralf, Altena, Ellemarije, Housden, Charlotte R., Maxwell, Helen, Sahakian, Barbara J., Barker, Roger A., Robbins, Trevor W., Rowe, James B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4819701/
https://www.ncbi.nlm.nih.gov/pubmed/26757216
http://dx.doi.org/10.1002/hbm.23087

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4819701/
https://www.ncbi.nlm.nih.gov/pubmed/26757216
http://dx.doi.org/10.1002/hbm.23087

Ejemplares similares